Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors

Histone deacetylase inhibitors (HDIs) are promising new agents for the treatment of haematological malignancy including lymphoma. MyD88 expression and secretion of pro-inflammatory cytokines may contribute to the sensitization of cancer cells to HDI. Moreover, MyD88 may be a direct target for HDAC- and BRD- inhibitors. Therefore, both expression level of MyD88 and MyD88 mutation status could serve as potential biomarkers for HDI sensitivity in patient selection

Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors

Histone deacetylase inhibitors (HDIs) are promising new agents for the treatment of haematological malignancy including lymphoma. MyD88 expression and secretion of pro-inflammatory cytokines may contribute to the sensitization of cancer cells to HDI. Moreover, MyD88 may be a direct target for HDAC- and BRD- inhibitors. Therefore, both expression level of MyD88 and MyD88 mutation status could serve as potential biomarkers for HDI sensitivity in patient selection

Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors

Histone deacetylase inhibitors (HDIs) are promising new agents for the treatment of haematological malignancy including lymphoma. MyD88 expression and secretion of pro-inflammatory cytokines may contribute to the sensitization of cancer cells to HDI. Moreover, MyD88 may be a direct target for HDAC- and BRD- inhibitors. Therefore, both expression level of MyD88 and MyD88 mutation status could serve as potential biomarkers for HDI sensitivity in patient selection

CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives

While more than half of non-Hodgkin lymphomas (NHL) can be cured with modern frontline chemoimmunotherapy regimens, outcomes of relapsed and/or refractory (r/r) disease in subsequent lines remain poor, particularly if considered ineligible for hematopoietic stem cell transplantation. Hence, r/r NHLs represent a population with a high unmet medical need. This therapeutic gap has been partially filled by adoptive immunotherapy. CD19-directed autologous chimeric antigen receptor (auto-CAR) T cells have been transformative in the treatment of patients with r/r B cell malignancies. Remarkable response rates and prolonged remissions have been achieved in this setting, leading to regulatory approval from the U.S. Food and Drug Administration (FDA) of four CAR T cell products between 2017 and 2021. This unprecedented success has created considerable enthusiasm worldwide, and autologous CAR T cells are now being moved into earlier lines of therapy in large B cell lymphoma. Herein, we summarize the current practice and the latest progress of CD19 auto-CAR T cell therapy and the management of specific toxicities and discuss the place of allogeneic CAR T development in this setting

Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma

Multiple myeloma remains an incurable disease, with a large proportion of patients in the relapsed/refractory setting often unable to achieve durable responses. Novel, well-tolerated and highly effective therapies in this patient population represent an unmet need. Preclinical studies have shown that B-cell maturation antigen is nearly exclusively expressed on normal and malignant plasma cells, thereby identifying it as a highly selective target for immunotherapeutic approaches. Belantamab mafodotin (GSK2857916, belamaf) is a first-in-class antibody–drug conjugate directed at B-cell maturation antigen and has shown promising activity in clinical trials. In this review, we provide an overview of belantamab mafodotin as a compound and present the available clinical efficacy and safety data in the treatment of relapsed/refractory multiple myeloma. </jats:p